Yenidoğanın Endokrin Acilleri
Synopsis
Neonatal endocrine emergencies are rare disorders that are clinically challenging to detect yet carry vital significance for infant survival. The document details the diagnostic and therapeutic approaches for commonly encountered conditions in neonates, including hyperbilirubinemia, hypoglycemia, congenital hypothyroidism, neonatal thyrotoxicosis, and congenital adrenal hyperplasia (CAH). Jaundice, which affects most newborns, can cause permanent brain damage such as bilirubin-induced neurological dysfunction and kernicterus; thus, it is closely monitored via transcutaneous or serum measurements and treated using phototherapy, exchange transfusion, and IVIG. Neonatal hypoglycemia, resulting from disrupted glucose homeostasis during postnatal adaptation, presents with neurogenic symptoms like sweating and tachycardia, as well as neuroglycopenic signs such as apnea, seizures, and coma, and is managed through early feeding, IV dextrose, steroids, and diazoxide. Congenital hypothyroidism, the most common preventable cause of mental retardation in childhood, is diagnosed through heel-prick TSH screening in the early days of life and managed with prompt Levothyroxine replacement. Neonatal thyrotoxicosis, which carries a risk of high mortality and heart failure if untreated, is treated with agents such as methimazole, propranolol, and hydrocortisone. Finally, CAH, most frequently caused by 21-hydroxylase deficiency, leads to salt-wasting crises and ambiguous genitalia in female infants due to cortisol and aldosterone deficiencies, necessitating urgent replacement therapy with hydrocortisone and fludrocortisone.
References
Practice parameter: management of hyperbilirubinemia in the healthy term newborn. American Academy of Pediatrics. Provisional Committee for Quality Improvement and Subcommittee on Hyperbilirubinemia. Pediatrics 1994; 94(4 Pt 1): 558-565.
Johnson L, Bhutani VK. The Clinical Syndrome of Bilirubin-Induced Neurologic Dysfunction. Seminars in Perinatology 2011; 35(3): 101-113. doi: https://doi.org/10.1053/j.semperi.2011.02.003.
Watchko JF, Tiribelli C. Bilirubin-induced neurologic damage--mechanisms and management approaches. N Engl J Med 2013; 369(21): 2021-2030. doi: 10.1056/NEJMra1308124.
Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2004; 114(1): 297-316. doi: 10.1542/peds.114.1.297.
Maisels MJ, Bhutani VK, Bogen D, et al. Hyperbilirubinemia in the newborn infant > or =35 weeks' gestation: an update with clarifications. Pediatrics 2009; 124(4): 1193-1198. doi: 10.1542/peds.2009-0329.
Maisels MJ, Kring E. Transcutaneous bilirubin levels in the first 96 hours in a normal newborn population of > or = 35 weeks' gestation. Pediatrics 2006; 117(4): 1169-1173. doi: 10.1542/peds.2005-0744.
Maisels MJ. Use TcB as a screening tool for jaundiced newborns. AAP News 2004; 25(1): 9-13.
Rübo J, Albrecht K, Lasch P, et al. High-dose intravenous immune globulin therapy for hyperbilirubinemia caused by Rh hemolytic disease. J Pediatr 1992; 121(1): 93-97. doi: 10.1016/s0022-3476(05)82551-x.
Smits-Wintjens VE, Walther FJ, Rath ME, et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics 2011; 127(4): 680-686. doi: 10.1542/peds.2010-3242.
Thompson-Branch A, Havranek T. Neonatal Hypoglycemia. Pediatr Rev 2017; 38(4): 147-157. doi: 10.1542/pir.2016-0063.
Adamkin DH. Postnatal glucose homeostasis in late-preterm and term infants. Pediatrics 2011; 127(3): 575-579. doi: 10.1542/peds.2010-3851.
Srinivasan G, Pildes RS, Cattamanchi G, et al. Plasma glucose values in normal neonates: a new look. J Pediatr 1986; 109(1): 114-117. doi: 10.1016/s0022-3476(86)80588-1.
Stanley CA, Rozance PJ, Thornton PS, et al. Re-evaluating "transitional neonatal hypoglycemia": mechanism and implications for management. J Pediatr 2015; 166(6): 1520-1525.e1521. doi: 10.1016/j.jpeds.2015.02.045.
Alsaleem M, Saadeh L, Kamat D. Neonatal hypoglycemia: a review. Clinical pediatrics 2019; 58(13): 1381-1386.
Montassir H, Maegaki Y, Ogura K, et al. Associated factors in neonatal hypoglycemic brain injury. Brain and Development 2009; 31(9): 649-656. doi: https://doi.org/10.1016/j.braindev.2008.10.012.
Thornton PS, Stanley CA, De Leon DD, et al. Recommendations from the Pediatric Endocrine Society for Evaluation and Management of Persistent Hypoglycemia in Neonates, Infants, and Children. J Pediatr 2015; 167(2): 238-245. doi: 10.1016/j.jpeds.2015.03.057.
Wight N, Marinelli KA. ABM clinical protocol #1: guidelines for blood glucose monitoring and treatment of hypoglycemia in term and late-preterm neonates, revised 2014. Breastfeed Med 2014; 9(4): 173-179. doi: 10.1089/bfm.2014.9986.
Karlsen K. The STABLE program pre-transport post-resuscitation stabilization care of sick infants: guidelines for neonatal healthcare providers: learner manual: STABLE Program; 2006.
Sweet CB, Grayson S, Polak M. Management Strategies for Neonatal Hypoglycemia. The Journal of Pediatric Pharmacology and Therapeutics 2013; 18(3): 199-208. doi: 10.5863/1551-6776-18.3.199.
Puchalski ML, Russell TL, Karlsen KA. Neonatal Hypoglycemia: Is There a Sweet Spot? Crit Care Nurs Clin North Am 2018; 30(4): 467-480. doi: 10.1016/j.cnc.2018.07.004.
Jacob H, Peters C. Screening, diagnosis and management of congenital hypothyroidism: European Society for Paediatric Endocrinology Consensus Guideline. Arch Dis Child Educ Pract Ed 2015; 100(5): 260-263. doi: 10.1136/archdischild-2014-307738.
Murphy N, Hume R, van Toor H, et al. The hypothalamic-pituitary-thyroid axis in preterm infants; changes in the first 24 hours of postnatal life. J Clin Endocrinol Metab 2004; 89(6): 2824-2831. doi: 10.1210/jc.2003-030317.
Rastogi MV, LaFranchi SH. Congenital hypothyroidism. Orphanet J Rare Dis 2010; 5: 17. doi: 10.1186/1750-1172-5-17.
Loh TP, Sethi SK, Metz MP. Paediatric reference interval and biological variation trends of thyrotropin (TSH) and free thyroxine (T4) in an Asian population. J Clin Pathol 2015; 68(8): 642-647. doi: 10.1136/jclinpath-2015-202916.
Grant DB, Smith I, Fuggle PW, et al. Congenital hypothyroidism detected by neonatal screening: relationship between biochemical severity and early clinical features. Arch Dis Child 1992; 67(1): 87-90. doi: 10.1136/adc.67.1.87.
Wassner AJ. Congenital Hypothyroidism. Clin Perinatol 2018; 45(1): 1-18. doi: 10.1016/j.clp.2017.10.004.
Léger J, Olivieri A, Donaldson M, et al. European Society for Paediatric Endocrinology Consensus Guidelines on Screening, Diagnosis, and Management of Congenital Hypothyroidism. Hormone Research in Paediatrics 2014; 81(2): 80-103. doi: 10.1159/000358198.
Bongers-Schokking JJ, Resing WC, de Rijke YB, et al. Cognitive development in congenital hypothyroidism: is overtreatment a greater threat than undertreatment? J Clin Endocrinol Metab 2013; 98(11): 4499-4506. doi: 10.1210/jc.2013-2175.
Neal PR, Jansen RD, Lemons JA, et al. Unusual manifestations of neonatal hyperthyroidism. Am J Perinatol 1985; 2(3): 231-235. doi: 10.1055/s-2007-999957.
Ogilvy-Stuart AL. Neonatal thyroid disorders. Arch Dis Child Fetal Neonatal Ed 2002; 87(3): F165-171. doi: 10.1136/fn.87.3.f165.
Samuels SL, Namoc SM, Bauer AJ. Neonatal Thyrotoxicosis. Clin Perinatol 2018; 45(1): 31-40. doi: 10.1016/j.clp.2017.10.001.
Bonfig W. Growth and development in children with classic congenital adrenal hyperplasia. Curr Opin Endocrinol Diabetes Obes 2017; 24(1): 39-42. doi: 10.1097/med.0000000000000308.
Sharma R, Seth A. Congenital adrenal hyperplasia: issues in diagnosis and treatment in children. Indian J Pediatr 2014; 81(2): 178-185. doi: 10.1007/s12098-013-1280-8.
Müdürlüğü TCSBHSG (2021). Yenidoğan Metabolik ve Endokrin Hastalık Tarama Programı (NTP). (https://hsgm.saglik.gov.tr/tr/cocukergen-tp-liste/yenidogan_tarama_programi.html adresinden ulaşılmıştır).
Merke DP, Bornstein SR. Congenital adrenal hyperplasia. Lancet 2005; 365(9477): 2125-2136. doi: 10.1016/s0140-6736(05)66736-0.
Speiser PW, White PC. Congenital adrenal hyperplasia. N Engl J Med 2003; 349(8): 776-788. doi: 10.1056/NEJMra021561.
Parsa AA, New MI. Steroid 21-hydroxylase deficiency in congenital adrenal hyperplasia. J Steroid Biochem Mol Biol 2017; 165(Pt A): 2-11. doi: 10.1016/j.jsbmb.2016.06.015.
Podgórski R, Aebisher D, Stompor M, et al. Congenital adrenal hyperplasia: clinical symptoms and diagnostic methods. Acta Biochim Pol 2018; 65(1): 25-33. doi: 10.18388/abp.2017_2343.
Khattab A, Haider S, Kumar A, et al. Clinical, genetic, and structural basis of congenital adrenal hyperplasia due to 11β-hydroxylase deficiency. Proc Natl Acad Sci U S A 2017; 114(10): E1933-e1940. doi: 10.1073/pnas.1621082114.
White PC, Curnow KM, Pascoe L. Disorders of steroid 11 beta-hydroxylase isozymes. Endocr Rev 1994; 15(4): 421-438. doi: 10.1210/edrv-15-4-421.
El-Maouche D, Arlt W, Merke DP. Congenital adrenal hyperplasia. Lancet 2017; 390(10108): 2194-2210. doi: 10.1016/s0140-6736(17)31431-9.
Park E, Pearson NM, Pillow MT, et al. Neonatal endocrine emergencies: a primer for the emergency physician. Emerg Med Clin North Am 2014; 32(2): 421-435. doi: 10.1016/j.emc.2014.01.003.
Speiser PW, Azziz R, Baskin LS, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010; 95(9): 4133-4160. doi: 10.1210/jc.2009-2631.
Nimkarn S, New MI. Prenatal diagnosis and treatment of congenital adrenal hyperplasia. Horm Res 2007; 67(2): 53-60. doi: 10.1159/000096353.